Celgene Corp. (NASDAQ:CELG)’s share price shot up 2.4% during mid-day trading on Thursday . The stock traded as high as $107.36 and last traded at $107.17, with a volume of 3,780,151 shares trading hands. The stock had previously closed at $104.62.

Several research firms have issued reports on CELG. Zacks Investment Research cut shares of Celgene Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, May 3rd. Credit Suisse Group AG restated an “outperform” rating and set a $140.00 target price on shares of Celgene Corp. in a research note on Thursday, May 5th. Morgan Stanley restated a “hold” rating on shares of Celgene Corp. in a research note on Thursday, June 30th. Robert W. Baird restated a “buy” rating and set a $162.00 target price on shares of Celgene Corp. in a research note on Tuesday, April 26th. Finally, Bank of America Corp. restated a “buy” rating and set a $125.00 target price on shares of Celgene Corp. in a research note on Monday, April 25th. Six equities research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $138.51.

The firm has a market capitalization of $83.29 billion and a price-to-earnings ratio of 52.30. The firm has a 50 day moving average of $102.12 and a 200-day moving average of $103.14.

Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $1.32 EPS for the quarter, beating the Zacks’ consensus estimate of $1.29 by $0.03. The business earned $2.51 billion during the quarter, compared to analysts’ expectations of $2.59 billion. The firm’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.07 earnings per share. Analysts predict that Celgene Corp. will post $5.70 EPS for the current year.

In other news, insider Robert J. Hugin sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, June 20th. The stock was sold at an average price of $100.16, for a total value of $7,512,000.00. Following the completion of the sale, the insider now directly owns 1,122,201 shares in the company, valued at $112,399,652.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several hedge funds have bought and sold shares of the stock. Synovus Financial Corp boosted its stake in Celgene Corp. by 16.6% in the fourth quarter. Synovus Financial Corp now owns 8,571 shares of the biopharmaceutical company’s stock worth $1,027,000 after buying an additional 1,222 shares during the period. WMS Partners LLC boosted its stake in shares of Celgene Corp. by 20.9% in the fourth quarter. WMS Partners LLC now owns 8,669 shares of the biopharmaceutical company’s stock valued at $1,038,000 after buying an additional 1,500 shares during the last quarter. Genesee Valley Trust Co. boosted its stake in shares of Celgene Corp. by 4.2% in the fourth quarter. Genesee Valley Trust Co. now owns 8,820 shares of the biopharmaceutical company’s stock valued at $1,056,000 after buying an additional 359 shares during the last quarter. Investment Management of Virginia LLC boosted its stake in shares of Celgene Corp. by 63.0% in the fourth quarter. Investment Management of Virginia LLC now owns 9,043 shares of the biopharmaceutical company’s stock valued at $1,083,000 after buying an additional 3,495 shares during the last quarter. Finally, NBT Bank N A NY boosted its stake in shares of Celgene Corp. by 0.3% in the fourth quarter. NBT Bank N A NY now owns 9,248 shares of the biopharmaceutical company’s stock valued at $1,107,000 after buying an additional 30 shares during the last quarter.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.